Abstract:Background: Lung cancer is a leading cause of cancer death globally. Platinum-based chemotherapeutic medications are essential for treating advanced NSCLC, despite that drug resistance severely limits its effectiveness. Objective: In this study, we investigated the cytotoxic effect of metformin on cisplatin-resistant NSCLC cells (A549/DDP) and its potential mechanisms. Methods: Anti-lung cancer efficacy of metformin, cisplatin, and metformin combined with cisplatin was examined in A549 and A549/DDP cells. The cell counting kit-8 (CCK-8) assay was applied for measuring cell proliferation. CalcuSyn software was used to calculate the combination index and estimate the synergistic effect of metformin and cisplatin on cell proliferation. The cell apoptosis was analyzed by flow cytometry and the expression of apoptosis-related proteins, Bcl-2, Bax and caspase-3 were analyzed using Western blot. Futhermore, the expression of key nucleotide excision repair (NER) proteins, ERCC1, XPF, and XPA, was also analyzed using Western blot. Results: We found that metformin had dose-dependent antiproliferative effects on A549/DDP and A549 cells. The combination of metformin and cisplatin had higher effectiveness in inhibiting A549/DDP and A549 cell growth than either of the two drugs alone. Flow cytometry analysis indicated that the combined treatment could cause more cell apoptosis than the single-drug treatment. Consistently, the combined treatment decreased the expression of Bcl-2 protein and elevated the expression of Bax, and cleaved caspase-3 proteins. The expression level of ERCC1, XPF, and XPA proteins were lower in the combined treatment than in either of metformin and cisplatin treatment alone. Conclusions: Our study suggested that metformin and cisplatin had synergistic antitumorigenic effects in A549/DDP cells. The combination of cisplatin and metformin could be promising drug candidates to sensitize cisplatin-induced apoptosis through regulating nucleotide excision repair pathways in lung cancer.

Metformin Potentiates Rapamycin and Cisplatin in Gastric Cancer in Mice

Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy

Metformin-induced AMPK activation promotes cisplatin resistance through PINK1/Parkin dependent mitophagy in gastric cancer

Metformin Enhances Anti-Cancer Effects of Cisplatin in Meningioma Through AMPK-mTOR Signaling Pathways

Metformin Inhibited Esophageal Squamous Cell Carcinoma Proliferation in Vitro and in Vivo and Enhanced the Anti-Cancer Effect of Cisplatin

Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend

Metformin Potentiates the Anticancer Activities of Gemcitabine and Cisplatin Against Cholangiocarcinoma Cells in Vitro and in Vivo

Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling.

Preliminary Study on the Antagonistic Effect of Metformin on Cisplatinin Human Gastric Cancer MKN-45 Cellline

Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer

Metformin and MiR-365 Synergistically Promote the Apoptosis of Gastric Cancer Cells Via MiR-365-PTEN-AMPK Axis.

Prelimary studies on metformin activation of AMPK to make cisplatin induce hepatocellular carcinoma cells apoptosis

Metformin Sensitizes Prostate Cancer Cells to Radiation Through EGFR/p-DNA-PKCS in Vitro and in Vivo.

Metformin Potentiates Anti-Tumor Effect of Resveratrol on Pancreatic Cancer by Down-Regulation of VEGF-B Signaling Pathway.

Metformin Suppresses the Esophageal Carcinogenesis in Rats Treated with NMBzA Through Inhibiting AMPK/mTOR Signaling Pathway

Metformin Sensitizes Cisplatin-induced Apoptosis Through Regulating Nucleotide Excision Repair Pathway in Cisplatin-resistant Human Lung Cancer Cells

Metformin triggers the intrinsic apoptotic response in human AGS gastric adenocarcinoma cells by activating AMPK and suppressing mTOR/AKT signaling

Metformin Reverses The Drug Resistance Of Cisplatin In Irradiated Cne-1 Human Nasopharyngeal Carcinoma Cells Through Pecam-1 Mediated Mrps Down-Regulation

Metformin Sensitizes the Response of Oral Squamous Cell Carcinoma to Cisplatin Treatment Through Inhibition of NF-κB/HIF-1α Signal Axis

Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways

Metformin Suppresses Gastric Cancer Progression Through Calmodulin‑like Protein3 Secreted from Tumor‑associated Fibroblasts